UK multiple sclerosis risksharing scheme: A new natural history dataset and an improved Markov model
<p style="text-align:justify;">Objectives: In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised...
| Κύριοι συγγραφείς: | , , , , , , , |
|---|---|
| Μορφή: | Journal article |
| Γλώσσα: | English |
| Έκδοση: |
BMJ Publishing Group
2014
|